Clinical efficacy of intravitreal injection of Conbercept in treatment of diabetic macular edema
10.3969/j.issn.1674-8115.2017.05.016
- VernacularTitle:康柏西普对糖尿病性黄斑水肿的疗效评价
- Author:
Qinglei SUN
;
Yan YAN
;
Lina ZHU
;
Xiaoling QIN
;
Ye TAN
;
Jie LIU
;
Haibo TAN
;
Li NING
;
Lin LIU
- Keywords:
diabetic macular edema;
Conbercept;
the best corrected visual acuity;
central retinal thickness
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(5):652-655
- CountryChina
- Language:Chinese
-
Abstract:
Objective · To investigate the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema (DME).Methods · Eleven patients (17 eyes) with DME (inflammatory type) received intravitreal injection of Conbercept monthly. After the first treatment, the patients were treated on demand. Follow-up after treatment for more than 6 months, the best corrected visual acuity (BCVA), central retinal thickness (CRT),diminished rate of DME and result of fundusfluorescein angiography(FFA) of DME eyes before and after treatment were compared. Results · During a follow-up of 7-29 months [(12±7) months], the injections were given 1-10 times [(4±3) times]. The results showed that the treatment effects on improving BCVA (logMAR) and diminishing of CRT were significant (t=7.306, P=0.001; t=5.272, P=0.000). The diminished rate of DME of our patients was 76.5%. Conclusion · Intravitreal injection of Conbercept in the treatment of DME is effective on reducing macular edema and improving visual acuity.